<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01450176</url>
  </required_header>
  <id_info>
    <org_study_id>MAC-04-11</org_study_id>
    <secondary_id>3776-001</secondary_id>
    <nct_id>NCT01450176</nct_id>
  </id_info>
  <brief_title>Comparing Patient Satisfaction With Pataday or Bepreve</brief_title>
  <official_title>Comparing Patient Satisfaction Throughout the Day With PATADAY (OLOPATADINE HYDROCHLORIDE) 0.2% QD or BEPREVE (BEPOTASTINE BESILATE OPHTHALMIC SOLUTION) 1.5% BID</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McCabe Vision Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McCabe Vision Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare patient satisfaction with Pataday (Olopatadine&#xD;
      hydrochloride 0.2%) one daily (QD) and Bepreve (Bepotastine besilate ophthalmic solution&#xD;
      1.5%) two times a day (BID).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      5 week randomized study with 15 subjects using Pataday qd for 2 weeks, and the other 15&#xD;
      subjects using Bepreve BID for 2 weeks. Following a one-week washout period, the two groups&#xD;
      are given the opposite test article (TA) for 2 weeks. Subjects to complete daily diary&#xD;
      regarding effects of drug and are seen in clinic for 3 exams.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relief of ocular itching</measure>
    <time_frame>5 weeks</time_frame>
    <description>All day relief of ocular itching throughout the treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient preference</measure>
    <time_frame>5 weeks</time_frame>
    <description>Patient satisfaction, preference, and comfort with treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Eye Allergies</condition>
  <arm_group>
    <arm_group_label>Pataday once daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15 subjects will administer Pataday once daily for 2 weeks. Then these subjects will administer Bepreve twice daily for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bepreve twice daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bepreve twice daily for 2 weeks, then subjects will use Pataday once daily for 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olopatadine hydrochloride 0.2%</intervention_name>
    <description>1 drop in each eye once daily for 2 weeks</description>
    <arm_group_label>Pataday once daily</arm_group_label>
    <other_name>Pataday</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bepotastine besilate ophthalmic solution 1.5%</intervention_name>
    <description>1 drop in each eye twice daily for 2 weeks</description>
    <arm_group_label>Bepreve twice daily</arm_group_label>
    <other_name>Bepreve</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be male or female subjects of any racial/ethnic group.&#xD;
&#xD;
          -  Be at least 18 years of age or older.&#xD;
&#xD;
          -  Have a diagnosis of allergic conjunctivitis with active symptoms, with no concurrent&#xD;
             ocular allergy associated conditions and no plans to have ocular surgery during study&#xD;
             period.&#xD;
&#xD;
          -  Willing and able to return for all required visits and follow instructions from&#xD;
             investigator and staff.&#xD;
&#xD;
          -  Able to self-administer test article (TA) or have a caregiver available to instill all&#xD;
             doses of TA.&#xD;
&#xD;
          -  If a woman, capable of becoming pregnant, agrees to have pregnancy testing performed&#xD;
             at screening (must be negative) and agrees to use a medically acceptable form of birth&#xD;
             control (intrauterine device, birth control pill, patch or subcutaneous implant,&#xD;
             condoms, diaphragm, and abstinence) throughout the study duration and for at least one&#xD;
             week prior to and one week after completion of the study. Women considered capable of&#xD;
             becoming pregnant include all females who have experienced menarche and who have not&#xD;
             experienced menopause (as defined by amenorrhea for greater than 12 consecutive&#xD;
             months) or have not undergone successful surgical sterilization (hysterectomy,&#xD;
             bilateral tubal ligation, or bilateral oophorectomy).&#xD;
&#xD;
          -  Sign and date the informed consent form approved by an Institutional Review Board&#xD;
             (IRB)/Independent Ethics Committee (IEC).&#xD;
&#xD;
          -  Be willing/able to return for all required study visits, to follow instructions from&#xD;
             the study investigator and his/her staff, and to complete and return the Screening and&#xD;
             Subject Diaries.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have known hypersensitivity to BEPREVE or PATADAY or any of their components.&#xD;
&#xD;
          -  Are actively taking steroids or antihistamines during the study or within 7 days prior&#xD;
             to enrolling in the study.&#xD;
&#xD;
          -  Are pregnant, planning to become pregnant, or nursing/lactating.&#xD;
&#xD;
          -  Have a known history of alcohol or drug abuse.&#xD;
&#xD;
          -  Participated in a study of an investigational drug or device within the past 30 days&#xD;
             prior to enrolling in the study.&#xD;
&#xD;
          -  Have a presence of an active ocular infection (bacterial, viral or fungal), positive&#xD;
             history of an ocular herpetic infection, or preauricular lymphadenopathy at any visit.&#xD;
&#xD;
          -  Have any significant illness {eg: any autoimmune disease, or severe cardiovascular&#xD;
             disease (including arrhythmias)}that the Investigator feels could be expected to&#xD;
             interfere with the subject's safety or study parameters and/or put the subject at anyh&#xD;
             unnecessary risk.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>McCabe Vision Center</name>
      <address>
        <city>Murfreesboro</city>
        <state>Tennessee</state>
        <zip>37129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>October 7, 2011</study_first_submitted>
  <study_first_submitted_qc>October 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2011</study_first_posted>
  <last_update_submitted>January 8, 2014</last_update_submitted>
  <last_update_submitted_qc>January 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>eye</keyword>
  <keyword>itching</keyword>
  <keyword>allergies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olopatadine Hydrochloride</mesh_term>
    <mesh_term>Bepotastine besilate</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

